-
1.发明申请公开(公告)号：US20200298196A1
公开(公告)日：2020-09-24
申请号：US16495825
申请日：2018-11-30
申请人： G2GBIO, INC.
发明人： Heeyong LEE , Eunyoung SEOL , Kwonhyeok YOON
摘要： The present invention relates to a method for producing biodegradable microspheres having improved safety and storage stability, and a method for producing the same. The present invention provides a method for preparing said biodegradable microspheres while minimizing the morphological changes of microspheres and significantly reducing residual solvents.
-
公开(公告)号：US20230096928A1
公开(公告)日：2023-03-30
申请号：US17904133
申请日：2021-02-15
申请人： G2GBIO, INC.
发明人： Yongha NA , Dongpil WON , Yejin KIM , Juhan LEE , Heekyoung CHOE , Eunyoung SEOL , Heeyong LEE
摘要： The present invention relates to a pharmaceutical composition useful for prevention or treatment of diabetes, beta-cell function preservation, high blood pressure, hyperlipidemia, obesity, non-alcoholic steatohepatitis or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as it comprises a sustained-release microsphere comprising semaglutide, a pharmaceutically acceptable salt, hydrate or solvate thereof, and thereby, it can effectively inhibit fatal side-effects by preventing initial burst of a drug and comprise a high content of drug compared to a particle size, and therefore, it can minimize the patient's pain and inflammatory reaction that may occur during administration.
-
公开(公告)号：US20220023217A1
公开(公告)日：2022-01-27
申请号：US17312061
申请日：2019-12-17
申请人： G2GBIO, INC.
发明人： Heeyong LEE , Eunyoung SEOL , Yongha NA , Juhan LEE
摘要： The present disclosure relates to a sustained-release injection formulation comprising biodegradable polymer microspheres containing deslorelin as an active ingredient, and a preparation method therefor. The sustained-release microsphere injection containing deslorelin, according to the present disclosure, has good administrability and enables, with a single administration, a deslorelin drug to be maintained at an effective concentration for 6 months without rapid temporary release into the blood of an animal.
-
4.发明公开公开(公告)号：US20240358694A1
公开(公告)日：2024-10-31
申请号：US18764541
申请日：2024-07-05
申请人： G2GBIO, INC.
发明人： Heeyong LEE , Eunyoung SEOL , Kwonhyeok YOON
IPC分类号： A61K31/445 , A61K9/00 , A61K9/16
CPC分类号： A61K31/445 , A61K9/0019 , A61K9/1647
摘要： The present invention relates to a sustained-release injectable preparation comprising biodegradable polymer microspheres containing donepezil as an active ingredient, and a method for producing the same, and a sustained-release preparation of donepezil sustained-release microspheres having a high content of donepezil and a method for producing the same. It is possible to maximize the therapeutic effect by decreasing gastrointestinal side effects frequently encountered in conventional oral administration agents and increasing patients' compliance of medicines.
-
公开(公告)号：US20240293427A1
公开(公告)日：2024-09-05
申请号：US18654262
申请日：2024-05-03
申请人： G2GBIO, INC.
发明人： Geonho KIM , Jinwoo LEE , Hyejung JUNG , Jaemook CHOI , Jeongsu BYUN , Juhan LEE , Eunyoung SEOL , Heeyong LEE
IPC分类号： A61K31/573 , A61K9/00 , A61K9/16 , A61K31/27 , A61K31/407 , A61K31/445 , A61K31/522 , A61K31/5415 , A61K31/56 , A61K38/08 , A61K38/09 , A61K38/26 , A61P29/00
CPC分类号： A61K31/573 , A61K9/0019 , A61K9/1647 , A61K31/27 , A61K31/407 , A61K31/445 , A61K31/522 , A61K31/5415 , A61K31/56 , A61K38/08 , A61K38/09 , A61K38/26 , A61P29/00
摘要： The present invention is a pharmaceutical kit for combined parenteral administration, comprising a first formulation containing a first drug, and a second formulation containing a second drug and a parenteral drug delivery system, and it can be used for preventing, reducing or treating an inflammatory reaction of a subject caused by the parenteral drug delivery system of the second formulation, controlling decomposition of the parenteral drug delivery system contained in the second formulation, or increasing bioavailability of the second drug contained in the second formulation.
-
公开(公告)号：US20220257518A1
公开(公告)日：2022-08-18
申请号：US17625831
申请日：2020-07-13
申请人： G2GBIO, INC
发明人： Heeyong LEE , Eunyoung SEOL , Juhan LEE , Yeonkyeong LEE , Donghyun PARK , Heekyoung CHOE
摘要： The present invention relates to a sustained release microsphere for long-lasting injectable formulations comprising one or more active ingredients selected from the group consisting of rivastigmine and pharmaceutically acceptable poorly soluble salts thereof and a biodegradable polymer, and a long-lasting injectable formulation for preventing or treating Alzheimer's disease comprising the same and a method for preparing the microsphere, and it can reduce side effects of the patient's gastrointestinal tract, which are frequently seen in conventional oral administration agents, and increase the adaptability of taking medicine, thereby maximizing the therapeutic effect, by providing a long-lasting injectable formulation comprising a rivastigmine sustained release microsphere, which has a high content while effectively controlling the initial burst drug release.
-
公开(公告)号：US20210052768A1
公开(公告)日：2021-02-25
申请号：US16960366
申请日：2019-01-10
申请人： G2GBIO, INC.
发明人： Heeyong LEE , Eunyoung SEOL , Kwonhyeok Yoon , Yongha NA
摘要： The present disclosure relates to a polycaprolactone microsphere containing vitamin C, a filler including the same and a preparation method therefor. Provided is a polycaprolactone microsphere filler obtained by encapsulating vitamin C in polycaprolactone microspheres, which, when injected into a living body, exhibits a rapid collagen formation effect as well as a high tissue restoration property and maintains the effects for a long period of time, thereby showing excellent restoration or volume expansion or wrinkle improvement properties of soft tissues such as cheeks, breasts, nose, lips, and buttocks and reducing wrinkles.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.013 秒)
